摘要
目的 探讨贝伐珠单抗联合免疫治疗对非鳞非小细胞肺癌(NSNSCLC)患者疾病控制、血清肿瘤标志物水平和生存质量的影响。方法 将100例NSNSCLC患者,按照简单随机化法分为联合组和单一组,各50例。单一组患者给予免疫治疗(纳武利尤单抗),联合组患者给予贝伐珠单抗联合免疫治疗。比较两组患者疾病控制情况,比较治疗前后两组患者血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原50(CA50)、糖类抗原125(CA125)]、血清生长因子[血管内皮生长因子(VEGF)、转化生长因子-β_(1)(TGF-β_(1))]水平、卡氏评分(KPS)、肺癌患者生存质量测定量表(FACT-L)评分以及不良反应发生情况。结果 联合组患者的疾病控制率高于单一组(P<0.05)。治疗后两组患者血清CEA、CA50、CA125、VEGF、TGF-β_(1)水平均较治疗前降低,且联合组患者低于单一组(P<0.01)。治疗后两组患者KPS、FACT-L评分均较治疗前升高,且联合组患者高于单一组(P<0.01)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论NSNSCLC患者采用贝伐珠单抗联合免疫治疗,临床效果和安全性良好,且可提高生活质量。
Objective To explore the influences of combined bevacizumab and immunotherapy on disease control,serum tumor marker(STM) levels and quality of life in patients with non-squamous non-sma ll cell lu ng ca ncer(NSNSCLC).Methods A tota l of 100 NSNSCLC patients were d ivided into combination a nd single g roup with 50 cases in each according to simple ra ndomization.Single g roup received im mu notherapy(nivolumab) a nd combination g roup did bevacizumab combined with immunotherapy.Disease control status and such indexes were compared between two groups as the STMs(carcinoembryonic antigen [CEA],carbohydrate antigen 50 [CA50],carbohydrate antigen 125 [CA125])and serum growth factor levels(vascular endothelial growth factor [VEGF],transforming growth factor-β_1[TGF-β_1]),Kar nofsky Performance Scale(K PS) and Functional Assessment of Cancer Therapy-Lung(FACT-L) scores,and the occurrence of adverse reactions.Results The disease control rate was higher in combination than single group(P<0.05).After treatment the levels of serum CEA,CA50,CA125,VEGF and TGF-β_(1) in both groups lowered compared with pre-treatment and were lower in combination than single group(P<0.01).After treatment scores on the KPS and FACT-L in both groups elevated compared with pre-treatment and were higher in combination than single group(P<0.01).Inter-group difference in the total incidence of adverse reactions wasn't statistically significant(P>0.05).Conclusion The combination of bevacizumab and immunotherapy for NSNSCLC patients has better clinical effect and higher safety and can improve the quality of life.
作者
穆艳艳
张敬伟
袁小笋
徐赟
Mu Yanyan;Zhang Jingwei;Yuan Xiaosun;Xu Yun(Nanyang Central Hospital,Nanyang 473000,Henan,China)
出处
《临床心身疾病杂志》
CAS
2024年第2期65-68,98,共5页
Journal of Clinical Psychosomatic Diseases
